Product Comparison


  Merck 00006404741 Merck 00006404720 Glaxo Smith Kline 58160074021
McKesson # 544446 1030987 1223555
Description RotaTeq® Rotavirus Vaccine, Live, Oral Pentavalent Solution 2 mL RotaTeq® Rotavirus Vaccine, Live, Oral Pentavalent Solution 2 mL Rotarix® Rotavirus Vaccine, Live, Oral 10E6 / mL Solution 1.5 mL
Manufacturer # 000064047410000640472058160074021
Brand RotaTeq®RotaTeq®Rotarix®
Manufacturer MerckMerckGlaxo Smith Kline
Invoice ROTATEQ VAC, SUSP 2ML LIVE PENTAV (10/PK)ROTATEQ VAC, SUSP 2ML LIVE PENTAV (25/BX)ROTARIX, ORAL DOSING APPL 1.5ML (10/CT)
    Log In to Order   Log In to Order   Log In to Order

Comparison

Container Type Single-Dose TubeSingle-Dose TubePrefilled Oral Applicator
Country of Origin United StatesUnited StatesUnknown
Generic Drug Code 265002650024276
Generic Drug Name Rotavirus Vaccine, Live, Oral PentavalentRotavirus Vaccine, Live, Oral PentavalentRotavirus Vaccine, Live, Oral
NDC Number 000064047410000640472058160074021
Product Dating McKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 180 days
Strength 10E6 / mL
User Indicated for People 6 to 32 Weeks of AgeIndicated for People 6 to 32 Weeks of AgeIndicated for People 6 to 24 Weeks of Age
Volume 2 mL2 mL1.5 mL
Application Rotavirus VaccineRotavirus VaccineRotavirus Vaccine
Dosage Form SolutionSolutionSolution
Storage Requirements Requires RefrigerationRequires RefrigerationRequires Refrigeration
Type OralOralOral
UNSPSC Code 512016185120161851201618
Features and Benefits
  • The vaccination series consists of three ready-to-use liquid doses of RotaTeq* administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4 to 10 week intervals
  • 10 individually pouched single dose tubes
  • Each dose is supplied in a container consisting of a squeezable plastic dosing tube with a twist-off cap, allowing for direct oral administration
  • RotaTeq® is a vaccine indicated for the prevention of rotavirus gastroenteritis caused by types G1, G2, G3, G4, and G9
  • RotaTeq is approved for use in infants 6 weeks to 32 weeks of age
  • The vaccination series consists of three ready-to-use liquid doses of RotaTeq* administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4 to 10 week intervals
  • Each dose is supplied in a container consisting of a squeezable plastic dosing tube with a twist-off cap, allowing for direct oral administration
  • The dosing tube is contained in a pouch
  • Package of 25 individually pouched single-dose tubes